News
SESN
0.6288
0.00%
0.00
CARISMA THERAPEUTICS INC <CARM.O>: BAIRD CUTS TO NEUTRAL RATING; CUTS TARGET PRICE TO $1 FROM $10
Reuters · 12/12 06:13
CARISMA THERAPEUTICS INC <CARM.O>: BTIG CUTS TO NEUTRAL FROM BUY
Reuters · 12/10 08:31
CARISMA THERAPEUTICS INC - CHIEF FINANCIAL OFFICER, RICHARD MORRIS WILL LEAVE COMPANY EFFECTIVE DEC 31
Reuters · 12/09 13:30
CARISMA THERAPEUTICS, INC. <CARM.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $5 FROM $8
Reuters · 11/25 11:12
U.S. RESEARCH ROUNDUP-Domino's Pizza, Elastic NV, Snowflake
Reuters · 11/25 07:05
CARISMA UNVEILS PROMISING PRE-CLINICAL DATA ON ANTI-GPC3 IN VIVO CAR-M THERAPY FOR HEPATOCELLULAR CARCINOMA
Reuters · 11/08 12:30
CARISMA -ANTI-GPC3 IN VIVO CAR-M THERAPY WELL TOLERATED IN MOUSE MODELS, HIGHLIGHTING ITS POTENTIAL AS AN OFF--SHELF TREATMENT FOR GPC3+ SOLID TUMORS
Reuters · 11/08 12:30
Carisma Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Reuters · 11/07 15:10
CARISMA THERAPEUTICS INC: CASH & CASH EQUIVALENTS OF $26.9 MILLION EXPECTED TO FUND CO INTO Q3 OF 2025
Reuters · 11/07 12:30
CARISMA THERAPEUTICS Q3 OPERATING EXPENSES USD 16.529 MILLION
Reuters · 11/07 12:30
CARISMA THERAPEUTICS INC: GOT NOTICE OF FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD FROM NASDAQ
Reuters · 10/11 20:51
CARISMA THERAPEUTICS Q2 NET INCOME USD -11.162 MILLION
Reuters · 08/08 11:30
CARISMA THERAPEUTICS ANNOUNCES EXPANSION OF ITS SCIENTIFIC ADVISORY BOARD
Reuters · 08/06 11:30
More
Webull provides a variety of real-time SESN stock news. You can receive the latest news about Sesen Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SESN
Carisma Therapeutics Inc., formerly Sesen Bio, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing immunotherapies for patients with cancer and other serious disorders. Its platform is focused on engineered macrophages, cells that plays a role in both the innate and adaptive immune response. Its pipeline includes multiple chimeric antigen receptor (CAR) macrophages designed to target solid tumors by engineering a patient’s own immune cells. Its technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and cellular therapy for the treatment of human disease. The Company's pipeline includes CT-0508, CT-0525, CT-1119 and CT-0729. Its CT-0508 and CT-0525 is an ex vivo gene-modified autologous CAR-Macrophage cellular therapy to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2) metastasis. Its CT-1119 is a ex vivo gene-modified autologous CAR-Macrophage cellular therapy.